A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
The assay provides comprehensive genomic information to oncologists from a blood draw, using targeted next-generation sequencing of circulating cell-free DNA.
Following positive Phase II results, the company plans to seek US and EU approval for the CAR T-cell therapy in relapsed or refractory follicular lymphoma in 2021.
TargetCancer is activating two enrollment sites and setting up a remote consenting process so patients with rare cancers can be seen at local community hospitals.
The drug is now approved in Hong Kong, China, and Taiwan as an extended adjuvant treatment for adult patients with early-stage, HER2-positive breast cancer.
